Global Cell Therapy Market Reaches Inflection Point with $7 Billion Projection
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Mar 27 2026
0mins
Should l Buy IBRX?
Source: Newsfilter
- Market Growth: The global cell therapy manufacturing market is projected to exceed $7 billion in 2026 and reach $14 billion by 2035, indicating robust growth potential that drives demand for cell and gene therapies.
- FDA Regulatory Impact: The FDA's easing of manufacturing requirements accelerates the approval timeline for life-saving products, creating sustainable value for therapy developers like Avaí Bio, marking a historic shift in the industry.
- Strategic Production Capacity: As biologics production capacity becomes a coveted strategic asset, Avaí Bio and Austrianova have commenced manufacturing a Master Cell Bank of α-Klotho protein, ensuring high quality and consistency for future production.
- Innovative Technology Application: Avaí Bio's cell therapy products will be developed using the Cell-in-a-Box® encapsulation platform, aiming to provide durable anti-aging treatments for patients, signifying the company's successful pivot into biotechnology.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
Current: 7.760
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Shareholder Class Action Reminder
- Class Action Notice: Robbins LLP reminds all shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, that a class action has been filed to protect investor rights and seek compensation.
- False Statement Allegations: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the company's lead biologic product, ANKTIVA, leading investors to misunderstand its potential effects.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) indicated that Soon-Shiong's promotional claims misleadingly suggested that ANKTIVA could cure and prevent all cancers, resulting in a 21% drop in ImmunityBio's stock price to $7.42 per share on that day.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by May 26, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially misleading statements during this period, particularly regarding the efficacy of its cancer vaccine Anktiva, which has severely undermined investor confidence in the company's prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendations: Investors are advised to file for lead plaintiff status by May 26, 2026, to represent other investors in the class action, reflecting a strong emphasis on legal rights and expectations for improved corporate governance.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, highlighting concerns over potential financial losses among investors.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, rendering the company's statements about its business, operations, and prospects materially false and misleading, which could have long-term repercussions on the company's reputation and stock price.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to participate in potential recovery, indicating a proactive stance among investors to protect their rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Shareholder Class Action Reminder
- Class Action Notice: Robbins LLP reminds all shareholders who purchased ImmunityBio (NASDAQ: IBRX) securities between January 19, 2026, and March 25, 2026, that a class action has been filed to protect investor rights and seek compensation.
- False Statement Allegations: The complaint alleges that CEO Soon-Shiong materially overstated the capabilities of the company's lead biologic product, ANKTIVA, leading investors to misunderstand its potential effects.
- FDA Warning Letter Impact: On March 24, 2026, a warning letter from the U.S. Food and Drug Administration (FDA) indicated that Soon-Shiong's promotional claims misleadingly suggested that ANKTIVA could cure and prevent all cancers, resulting in a 21% drop in ImmunityBio's stock price to $7.42 per share on that day.
- Shareholder Action Guidance: Shareholders wishing to serve as lead plaintiffs in the class action must submit their papers to the court by May 26, 2026, while those who choose not to participate can remain absent class members and still retain their rights to recovery.
See More
ImmunityBio Faces Securities Fraud Class Action Lawsuit
- Lawsuit Announcement: Kessler Topaz Meltzer & Check, LLP has filed a securities fraud class action against ImmunityBio (NASDAQ:IBRX) for investors who purchased shares between January 19 and March 24, 2026, highlighting significant investor concerns regarding the company's financial transparency.
- False Statement Allegations: The lawsuit alleges that ImmunityBio made materially misleading statements during this period, particularly regarding the efficacy of its cancer vaccine Anktiva, which has severely undermined investor confidence in the company's prospects.
- FDA Warning Impact: On March 24, 2026, the FDA issued a warning letter to ImmunityBio, citing inaccurate claims made by executives about Anktiva on a podcast, resulting in a 21.12% drop in stock price to $7.42 per share, illustrating the direct impact of regulatory risks on the company's valuation.
- Investor Action Recommendations: Investors are advised to file for lead plaintiff status by May 26, 2026, to represent other investors in the class action, reflecting a strong emphasis on legal rights and expectations for improved corporate governance.
See More
ImmunityBio Faces Class Action Lawsuit for Securities Violations
- Class Action Initiated: Bronstein, Gewirtz & Grossman has filed a class action lawsuit against ImmunityBio, seeking damages for investors who purchased securities between January 19 and March 24, 2026, highlighting concerns over potential financial losses among investors.
- False Statement Allegations: The complaint alleges that ImmunityBio's executive Soon-Shion materially overstated Anktiva's capabilities, rendering the company's statements about its business, operations, and prospects materially false and misleading, which could have long-term repercussions on the company's reputation and stock price.
- Investor Action Call: Affected investors are encouraged to apply to be lead plaintiffs by May 26, 2026, to participate in potential recovery, indicating a proactive stance among investors to protect their rights.
- Law Firm Background: Bronstein, Gewirtz & Grossman is recognized for recovering hundreds of millions for investors, emphasizing its expertise in securities fraud class actions, which may bolster investor confidence in the case.
See More
ImmunityBio Faces Securities Class Action Lawsuit
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, highlighting misleading claims made by Chairman Soon-Shiong regarding Anktiva's efficacy, which resulted in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization and severely impacting investor confidence.
- Class Action Lawsuit Initiated: Hagens Berman has filed a securities class action lawsuit against ImmunityBio on behalf of investors who purchased securities between January 19 and March 24, 2026, alleging violations of federal securities laws that could lead to further losses for investors.
- Efficacy Claims Controversy: Soon-Shiong claimed in a podcast that Anktiva could treat all cancers, while the FDA stated that these promotional materials mislead the public and fail to provide complete information regarding Anktiva's FDA-approved indications, posing potential public health risks.
- Investor Rights Protection: Hagens Berman is urging investors who suffered significant losses to submit their information and is encouraging witnesses to assist in the investigation, demonstrating a commitment to protecting investor rights and pursuing corporate transparency.
See More
